Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, a move that strengthens the company's expertise in biotechnology, drug delivery, and central nervous system clinical development. The company is advancing its pipeline of novel serotonergic agonists (NSAs) for mental health conditions.
Dr. Langer, a renowned figure in biotechnology and drug delivery, brings decades of experience in developing innovative therapies. His appointment is expected to provide strategic guidance as Helus Pharma progresses its lead candidate, HLP003, through Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address unmet needs in mental health.
Dr. Brannan, an expert in central nervous system clinical development, adds depth to the advisory board's capabilities. His experience will be valuable as the company advances HLP004, a proprietary NSA in Phase 2 trials for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs aimed at promoting neuroplasticity through serotonin pathway activation.
The appointments underscore Helus Pharma's focus on disciplined, evidence-based drug development. According to the press release, the company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering potential durable improvements for individuals with depression, anxiety, and other mental health conditions. For more details, the full press release is available at https://ibn.fm/CyjTq.
Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve the treatment landscape with class-leading data from its NSA programs. Investors can find the latest news and updates at https://ibn.fm/HELP.
The addition of Dr. Langer and Dr. Brannan signals a strategic effort to enhance the company's scientific foundation as it targets major depressive disorder and generalized anxiety disorder, conditions with significant unmet medical needs. Their expertise is expected to accelerate the development of Helus Pharma's pipeline, potentially bringing new treatment options to patients.
